TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15821962

Group type: EXPERIMENTAL
Intervention: Coronary revascularization in 142 patients
Number of subjects: 253

Group type: COMPARATOR
Intervention: Medically treated in 111 patients
Number of subjects: 253
Study: 12117084

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 4% nasal solution
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150
Study: 9863701

Group type: EXPERIMENTAL
Intervention: 2-back task
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1-back task
Number of subjects: 7

Group type: COMPARATOR
Intervention: 0-back task
Number of subjects: 7
Study: 8549085

Group type: EXPERIMENTAL
Intervention: Bio-impedance spectroscopy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Multi-frequency bio-impedance analysis
Number of subjects: 29
Study: 2793699

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet with 53% of calories as carbohydrate (CB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet with 55% of calories as fat (FB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 5% dextrose plus electrolytes (D5W) infusion for 48 hours
Number of subjects: 16
Study: 669542

Group type: EXPERIMENTAL
Intervention: Benzopyrone preparation (Venalot)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (analgesic only)
Number of subjects: 295
Study: 31823314

Group type: EXPERIMENTAL
Intervention: Intervention practices received clinical quality measure (CQM) reports at least quarterly, hosted an on-site visit and 2 webinars, and sent clinician/staff representatives to a 'best practice' meeting.
Number of subjects: 107094

Group type: COMPARATOR
Intervention: Control practices received CQM reports at least quarterly.
Number of subjects: 107094
Study: 30636632

Group type: EXPERIMENTAL
Intervention: Minimally invasive spinal anesthesia using 27-gauge pen type fine spinal needles (experimental group, n = 110)
Number of subjects: 202

Group type: COMPARATOR
Intervention: 22-gauge traditional spinal needles (control group, n = 92)
Number of subjects: 202
Study: 27831502

Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab with chemotherapy (paclitaxel, epirubicin, cyclophosphamide)
Number of subjects: 396
Study: 26410801

Group type: EXPERIMENTAL
Intervention: Perineal massage (10‐minute perineal massage with glycerol four times during the first stage and once during the second stage of labor)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 284
Study: 23880548

Group type: EXPERIMENTAL
Intervention: Medicare model
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: VGNW model
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: BAR model
Number of subjects: 345
Study: 20943783

Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment for up to 4.5 years
Number of subjects: 81
Study: 19364963

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study: 17400953

Group type: COMPARATOR
Intervention: Copenhagen (moist snuff)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Commit (medicinal nicotine lozenge)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ariva (PREP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Revel (PREP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stonewall (PREP)
Number of subjects: 10
Study: 15213063

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11231439

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 10447840

Group type: EXPERIMENTAL
Intervention: Videotape feedback and lecture methods for teaching alcohol brief intervention skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture and demonstration about the principles and practice of brief alcohol intervention
Number of subjects: 0
Study: 7589046

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine retard 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined atenolol 100 mg and nifedipine retard 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam 5 mg (active control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2273526

Group type: EXPERIMENTAL
Intervention: Refusals skills training program
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 7468987

Group type: EXPERIMENTAL
Intervention: Pentazocine (higher dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pentazocine (lower dose)
Number of subjects: 28
Study: 31274119

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (4 doses of Norfloxacin 400mg, twice a day for two days)
Number of subjects: 251

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 251
Study: 27898215

Group type: EXPERIMENTAL
Intervention: Aggressive drainage (daily drainage)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard drainage (every other day drainage)
Number of subjects: 149
Study: 26003169

Group type: EXPERIMENTAL
Intervention: Extreme chromosomal instability (CIN) defined as MCD4 group tumours.
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Extreme chromosomal instability (CIN) in ER-negative/HER2-negative cancers.
Number of subjects: 1173
Study: 23218591

Group type: EXPERIMENTAL
Intervention: Music therapy (15 min prior to radiation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (15 min rest prior to radiation)
Number of subjects: 200
Study: 22072355

Group type: EXPERIMENTAL
Intervention: Perioperative immune-enhancing formula for malnourished patients (DS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pre-surgical dietetic guidance and intravenous fluids for malnourished patients (DNS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Perioperative nutritional support (DS)
Number of subjects: 50
Study: 19698938

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) with medication
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT) without medication
Number of subjects: 76
Study: 17198061

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 18
Study: 15099320

Group type: EXPERIMENTAL
Intervention: 1% tretinoin peel
Number of subjects: 10

Group type: COMPARATOR
Intervention: 70% glycolic acid
Number of subjects: 10
Study: 11445484

Group type: EXPERIMENTAL
Intervention: Infertile men (n = 66)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fertile men (n = 10)
Number of subjects: 76
Study: 11352879

Group type: EXPERIMENTAL
Intervention: Prolonged antiplatelet therapy (6 months of clopidogrel and aspirin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active gamma‐radiation treatment (1 month of antiplatelet therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo historical control group (1 month of antiplatelet therapy)
Number of subjects: 120
Study: 9248985

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 8491318

Group type: EXPERIMENTAL
Intervention: Suturing of skin flaps to underlying muscle
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional skin closure
Number of subjects: 39
Study: 3622314

Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide 5-mononitrate 60 mg once daily
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide 60 mg once daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional formulation of isosorbide 20 mg 3 times daily
Number of subjects: 136
Study: 1982280

Group type: EXPERIMENTAL
Intervention: 5 mg epinastine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg epinastine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 mg epinastine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 4207965

Group type: EXPERIMENTAL
Intervention: Vitamin D(2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30251299

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) breathing with a 5-cm H2O expiratory load
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham (no load)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) breathing
Number of subjects: 13
Study: 28321027

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Azosemide
Number of subjects: 21
Study: 26561784

Group type: EXPERIMENTAL
Intervention: 2.5 g bioactive collagen peptides (BCP) daily for 6 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 25177910

Group type: EXPERIMENTAL
Intervention: Novel weight-loss intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 20884344

Group type: EXPERIMENTAL
Intervention: Hypoxic-absolute exercise (50%W(max) under 15%O₂, H-AT) for 30 min/day, 5 days/week for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normoxic resting (N-C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hypoxic resting (H-C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normoxic exercise (N-T)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hypoxic-relative exercise (H-RT)
Number of subjects: 50
Study: 19808198

Group type: EXPERIMENTAL
Intervention: MAGE‐A3 antigen‐specific cancer immunotherapeutic (ASCI) agents
Number of subjects: 0
Study: 17582289

Group type: EXPERIMENTAL
Intervention: Fourth quartile group of MPO level
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: MPO level > or = 62.9 AUU/L
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: MPO level when TnI <= 0.05 ng/ml
Number of subjects: 176
Study: 15364316

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Control (placebo with open-label antihypertensive therapy)
Number of subjects: 1518
Study: 12389143

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Gabapentin 2000 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 62
Study: 9661119

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg recombinant human growth hormone (rhGH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg recombinant human growth hormone (rhGH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg rhGH
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rhGH
Number of subjects: 8
Study: 8748042

Group type: EXPERIMENTAL
Intervention: d‐fenfluramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2497136

Group type: EXPERIMENTAL
Intervention: 100% CO2
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% CO2 in air
Number of subjects: 0
Study: 408287

Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone (Tanderil)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30312586

Group type: EXPERIMENTAL
Intervention: Vazirani‐Akinosi (VA) nerve block
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve (IAN) block
Number of subjects: 200
Study: 28279967

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25906824

Group type: EXPERIMENTAL
Intervention: Centers for Medicare & Medicaid Services hospital-acquired conditions policy
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Postpolicy period
Number of subjects: 569
Study: 23425012

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 to 5 mg
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study: 21188654

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs‐Tx)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no cell therapy)
Number of subjects: 56
Study: 19690393

Group type: EXPERIMENTAL
Intervention: Right Ventricular Apex (RVA) pacing
Number of subjects: 122

Group type: COMPARATOR
Intervention: Right Ventricular Outflow Tract (RVOT) pacing
Number of subjects: 122
Study: 17377401

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) - 2 puffs administered at 0, 20, 40 min
Number of subjects: 21

Group type: COMPARATOR
Intervention: Terbutaline (T) - 2 puffs administered at 0, 20, 40 min
Number of subjects: 21
Study: 15188805

Group type: EXPERIMENTAL
Intervention: Phenobarbital 20 mg/kg i.v. within first six hours of life
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11683930

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus AMPC 750 mg and CAM 200 mg b.i.d. (Group B-LAC200)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg, AMPC 750 mg and CAM 400 mg b.i.d. (Group C-LAC400)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPZ 30 mg twice a day (Group A-LPZ-only)
Number of subjects: 0
Study: 10530103

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (RMGI) restorative materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional composite resin
Number of subjects: 0
Study: 7915733

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study: 2917701

Group type: COMPARATOR
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily) + Lovastatin (20 mg twice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lovastatin alone
Number of subjects: 16
Study: 4897625

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (water test meal)
Number of subjects: 0
Study: 30142037

Group type: EXPERIMENTAL
Intervention: Conventional tray-delivered system (10% hydrogen peroxide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Strips (White Strips, Oral-B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prefilled disposable trays (Opalescence Go, Ultradent)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (10% hydrogen peroxide)
Number of subjects: 60
Study: 30020943

Group type: EXPERIMENTAL
Intervention: Chewing an apple
Number of subjects: 20

Group type: COMPARATOR
Intervention: Brushing teeth
Number of subjects: 20
Study: 29906024

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 68
Study: 24271159

Group type: EXPERIMENTAL
Intervention: Extralevator abdominoperineal excision (ELAPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard abdominoperineal excision (SAPE)
Number of subjects: 20
Study: 22424039

Group type: EXPERIMENTAL
Intervention: Exploration and salvage of superficial branches of the saphenous nerve
Number of subjects: 98

Group type: COMPARATOR
Intervention: No exploration of the saphenous nerve
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overall population of 98 patients
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 98
Study: 19486269

Group type: EXPERIMENTAL
Intervention: oral and denture hygiene instructions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: instructions associated with the home use of a disclosing agent (1% neutral red)
Number of subjects: 11
Study: 17498020

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg x kg(‐1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 microg x kg(‐1)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 93
Study: 15682849

Group type: EXPERIMENTAL
Intervention: Tc‐99m ethylenedicysteine (3.7 MBq/kg body weight) and furosemide at an appropriate dose administered intravenously
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: F+0 diuresis renography
Number of subjects: 133
Study: 11568738

Group type: EXPERIMENTAL
Intervention: High-dose UVA1 phototherapy (<=130 J/cm2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medium-dose UVA1 phototherapy (half the dose of high-dose)
Number of subjects: 10
Study: 9586911

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, and prednisone (COP)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Prednimustine and mitoxantrone (PmM)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) maintenance
Number of subjects: 234

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 234
Study: 7978187

Group type: EXPERIMENTAL
Intervention: etomidate-fentanyl
Number of subjects: 19

Group type: COMPARATOR
Intervention: midazolam-fentanyl
Number of subjects: 19
Study: 2594037

Group type: EXPERIMENTAL
Intervention: Combination therapy (3000 cGy of electron-beam radiation + parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sequential topical treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Combination therapy and Sequential topical treatment
Number of subjects: 103
Study: 4804456

Group type: EXPERIMENTAL
Intervention: Low-calorie diet alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-calorie diet with fenfluramine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diabetics not on any form of treatment
Number of subjects: 23
Study: 31979019

Group type: EXPERIMENTAL
Intervention: Fiber-enriched food products
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fiber-enriched drinks
Number of subjects: 29
Study: 31409915

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg in addition to baseline dose of statin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Double-dose statin therapy
Number of subjects: 21
Study: 29020936

Group type: EXPERIMENTAL
Intervention: Staggered sugammadex (1 mg/kg before extubation and 1 mg/kg after extubation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single bolus sugammadex (2 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neostigmine (0.02 mg/kg with glycopyrrolate)
Number of subjects: 120
Study: 25835160

Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23455877

Group type: EXPERIMENTAL
Intervention: Methadone with counseling for 4 months followed by standard methadone with counseling
Number of subjects: 230

Group type: COMPARATOR
Intervention: Methadone without counseling for 4 months followed by standard methadone with counseling
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Methadone treatment (both with and without counseling)
Number of subjects: 230
Study: 21909060

Group type: EXPERIMENTAL
Intervention: Sensorial saturation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Glucose solution
Number of subjects: 28
Study: 18237355

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 448

Group type: COMPARATOR
Intervention: Cisplatin monotherapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Alternative treatments (MVP, vinorelbine, active symptom control)
Number of subjects: 448
Study: 17214378

Group type: EXPERIMENTAL
Intervention: Viewing from the central position with the near row having more lights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing from a lateral position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-dimensional stimuli
Number of subjects: 0
Study: 12828724

Group type: EXPERIMENTAL
Intervention: Cyto-SED™ system (CS)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Direct smear (DS) technique
Number of subjects: 137
Study: 10987238

Group type: EXPERIMENTAL
Intervention: Standard therapy plus manual lymphatic drainage (MLD) 8 times in 2 weeks and training in self-massage
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard therapy (compression garment, exercises, information about lymphedema and skin care)
Number of subjects: 42
Study: 8993089

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8291869

Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate (PEP) 160 mg/month
Number of subjects: 147

Group type: COMPARATOR
Intervention: LHRH analog (buserelin)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 147
Study: 3034016

Group type: EXPERIMENTAL
Intervention: Ramipril (HOE 498) 5 or 10 mg
Number of subjects: 34
Study: 31197506

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium lactis
Number of subjects: 97

Group type: COMPARATOR
Intervention: Non-probiotic formula
Number of subjects: 97
Study: 29790415

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390
Study: 24507830

Group type: EXPERIMENTAL
Intervention: High-dose fluticasone (1,000 μg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-dose fluticasone (250 μg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Repeated measurements of PC20
Number of subjects: 64
Study: 23129488

Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg to 12 mg depending on response)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 20233199

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg)
Number of subjects: 20
Study: 18621928

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg once daily
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg once daily
Number of subjects: 543

Group type: COMPARATOR
Intervention: Standard therapy (low-molecular-weight heparin followed by vitamin K antagonists)
Number of subjects: 543
Study: 16100132

Group type: EXPERIMENTAL
Intervention: Disease management (DM) program with care coordination, family support, teaching, and monitoring of therapies from a team of advanced-practice nurses, a geriatrician, and a pulmonologist for 2 months post-hospital discharge.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Disease management (DM) program.
Number of subjects: 334